Champions Oncology (NASDAQ:CSBR) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. “

Separately, Craig Hallum initiated coverage on shares of Champions Oncology in a research report on Tuesday, July 17th. They set a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $11.33.

NASDAQ:CSBR opened at $12.59 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.73 and a quick ratio of 0.73. The company has a market cap of $145.03 million, a P/E ratio of -89.93 and a beta of 0.57. Champions Oncology has a fifty-two week low of $3.05 and a fifty-two week high of $17.90.

Champions Oncology (NASDAQ:CSBR) last posted its quarterly earnings data on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.03. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $5.85 million. Champions Oncology had a negative net margin of 1.63% and a negative return on equity of 97.02%. As a group, equities analysts forecast that Champions Oncology will post 0.17 EPS for the current year.

In related news, Director Daniel Newman Mendelson sold 8,333 shares of the stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $13.02, for a total transaction of $108,495.66. Following the completion of the transaction, the director now owns 62,500 shares of the company’s stock, valued at approximately $813,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joel Ackerman sold 22,535 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $17.02, for a total transaction of $383,545.70. Following the transaction, the director now directly owns 1,021,731 shares of the company’s stock, valued at approximately $17,389,861.62. The disclosure for this sale can be found here. Insiders have sold a total of 35,868 shares of company stock valued at $560,791 in the last ninety days. 44.30% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of CSBR. Perkins Capital Management Inc. purchased a new position in Champions Oncology in the 2nd quarter valued at approximately $653,000. Acadian Asset Management LLC purchased a new position in Champions Oncology in the 3rd quarter valued at approximately $1,249,000. Tocqueville Asset Management L.P. purchased a new position in Champions Oncology in the 2nd quarter valued at approximately $729,000. Renaissance Technologies LLC boosted its position in Champions Oncology by 63.3% in the 2nd quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock valued at $638,000 after buying an additional 39,000 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new position in Champions Oncology in the 3rd quarter valued at approximately $344,000. 41.21% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

See Also: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.